Abstract:Viral hepatitis C infection is one of the main causes of the hepatitis after blood transfusion and hepatitis C virus (HCV) infection is a global health threat. The HCV NS5B polymerase, an RNA dependent RNA polymerase (RdRp) and an essential role in the replication of the virus, has no functional equivalent in mammalian cells. So the research and development of efficient NS5B polymerase inhibitors provides a great strategy for antiviral therapy against HCV. A combined three-dimensional quantitative structure activity relationship (QSAR) modeling was accomplished to profoundly understand the structure activity correlation of a train of indole-based inhibitors of the HCV NS5B polymerase to against HCV. A comparative molecular similarity indices analysis (COMSIA) model as the foundation of the maximum common substructure alignment was developed. The optimum model exhibited statistically significant results: the cross-validated correlation coefficient q(2) was 0.627 and non-cross-validated r2 value was 0.943. In addition, the results of internal validations of bootstrapping and Y-randomization confirmed the rationality and good predictive ability of the model, as well as external validation (the external predictive correlation coefficient Lixt = 0.629). The information obtained from the COMSIA contour maps enables the interpretation of their structure activity relationship. Furthermore, the molecular docking study of the compounds for 3TYV as the protein target revealed important interactions between active compounds and amino acids, and several new potential inhibitors with higher activity predicted were designed basis on our analyses and supported by the simulation of molecular docking. Meanwhile, the OSIRIS Property Explorer was introduced to help select more satisfactory compounds. The satisfactory results from this study may lay a reliable theoretical base for drug development of hepatitis C virus NS5B polymerase inhibitors. (C) 2016 Elsevier B.V. All rights reserved.

Inhibition of Hepatitis C Virus Infection by Polyoxometalates

Inhibitory Effect of Novel Polyoxometalate on Hepatitis B Virus Replication in Vitro

Antiviral Activity of Cuprous Oxide Nanoparticles Against Hepatitis C Virus in Vitro

Anti-flavivirus Activity of Polyoxometalate

Inhibition of Hepatitis E Virus Replication by Peptide-Conjugated Morpholino Oligomers

2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action

2-Octynoic Acid Inhibits Hepatitis C Virus Infection Through Activation of AMP-Activated Protein Kinase

3D-QSAR and Molecular Docking Studies on Designing Inhibitors of the Hepatitis C Virus NS5B Polymerase

Oxymatrine inhibits target cell infection in the HCVcc system

Discovery of Novel 3-Hydroxyquinazoline-2,4(1h,3h)-dione Derivatives: A Series of Metal Ion Chelators with Potent Anti-HCV Activities.

A novel class of meso-tetrakis-porphyrin derivatives exhibits potent activities against hepatitis C virus genotype 1b replicons in vitro

Anti-influenza A(H5N1) virus activities of a novel polyoxometalate in vitro and in vivo

A P7 Ion Channel-derived Peptide Inhibits Hepatitis C Virus Infection in Vitro

Inhibition of hepatitis C virus infection by NS5A-specific aptamer.

Discovery of Novel Small Molecule Anti-HCV Agents via the CypA Inhibitory Mechanism Using O-Acylation-Directed Lead Optimization

Inhibition of hepatitis C virus infection by DNA aptamer against NS2 protein

Anti-RNA Virus Activity of Polyoxometalates.

Discovering novel anti-HCV compounds with inhibitory activities toward HCV NS3/4A protease

Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure-Activity Relationships

Development Of Oleanane-Type Triterpenes As A New Class Of Hcv Entry Inhibitors

Oxymatrine inhibits hepatitis B infection with an advantage of overcoming drug-resistance